Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 16 of the 37 sources its claims cite were checked for support.
Abstract
Background: Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disease evolution or treatment responses in patients. Here, we have studied the relationship between fluid biomarkers of neurodegeneration and synaptic dysfunction in patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and subjective cognitive decline (SCD). Methods: The exploratory cohort consisted of cerebrospinal fluid (CSF) samples (n = 60) from patients diagnosed with AD (n = 20), FTD (n = 20), and SCD (n = 20) from the Amsterdam Dementia Cohort. We developed two novel immunoassays for the synaptic proteins synaptosomal-associated protein-25 (SNAP25) and vesicle-associated membrane protein-2 (VAMP2). We measured the levels of these biomarkers in CSF, in addition to neuronal pentraxin-2 (NPTX2), glutamate ionotropic receptor-4 (GluR4), and neurogranin (Ng) for this cohort. All in-house immunoassays were validated and analytically qualified prior to clinical application. CSF neurogranin (Ng) was measured using a commercially available ELISA. Results: This pilot study indicated that SNAP25, VAMP2, and Ng may not be specific biomarkers for AD as their levels were significantly elevated in patients with both AD and FTD compared to SCD. Moreover, the strength of the correlations between synaptic proteins was lower in the AD and FTD clinical groups compared to SCD. SNAP25, VAMP2, and Ng correlated strongly with each other as well as with total Tau (Tau) and phosphorylated Tau (PTau) in all three clinical groups. However, this correlation was weakened or absent with NPTX2 and GluR4. None of the synaptic proteins correlated to neurofilament light (NfL) in any clinical group. Conclusion: The correlation of the synaptic biomarkers with CSF Tau and PTau but the lack thereof with NfL implies that distinct pathological pathways may be involved in synaptic versus axonal degeneration. Our results reflect the diversity of synaptic pathology in neurodegenerative dementias.
Overview
CoChat Summary
TL;DR
This pilot study measured CSF synaptic proteins SNAP25, VAMP2, Ng, NPTX2, and GluR4 in patients with AD, FTD, and SCD (n = 60) and found that SNAP25, VAMP2, and Ng were elevated in both AD and FTD versus SCD, with differential correlations to Tau/PTau but not NfL. The authors also developed and analytically validated novel VAMP2 ELISA and SNAP25 Simoa immunoassays.
Key findings
- CSF SNAP25, VAMP2, and Ng were significantly higher in both AD and FTD than SCD; SNAP25 alone was significantly elevated in AD versus FTD. NPTX2 was significantly lower in FTD than SCD, while GluR4 did not differ across groups.
- Diagnostic AUCs: SNAP25 was 0.99 for AD vs SCD, 0.83 for FTD vs SCD, and 0.75 for AD vs FTD. Selected panels were SNAP25 alone for AD vs SCD (AUC = 0.99), VAMP2 + NPTX2 for FTD vs SCD (AUC = 0.97), and SNAP25 + VAMP2 for AD vs FTD (AUC = 0.84).
- SNAP25, VAMP2, and Ng correlated with Tau and PTau in all three clinical groups (Pearson r = 0.94–0.55), but no synaptic protein correlated with NfL in any group. Correlations among synaptic proteins were lower in AD and FTD than in SCD (SCD r = 0.92–0.49; AD/FTD r = 0.73–0.58).
- In the overall cohort, SNAP25 (Spearman r = −0.57), VAMP2 (r = −0.48), and Ng (r = −0.52) were negatively correlated with MMSE (P < 0.001); in AD patients, NPTX2 correlated with MMSE (r = 0.55, P = 0.012).
Methods
- Exploratory CSF cohort from the Amsterdam Dementia Cohort: n = 60 patients with AD (n = 20), FTD (n = 20; all “probable behavioral” variant), and SCD (n = 20). Core biomarkers Aβ42, Tau, PTau, and NfL were available; SCD individuals were negative for AD biomarkers.
- The authors developed a novel VAMP2 sandwich ELISA and a SNAP25 Simoa assay, validated for precision, LLOQ, dilutional linearity, and parallelism, and measured SNAP25, VAMP2, NPTX2, GluR4, and Ng in CSF.
- Analyses included Kruskal–Wallis with Dunn’s post hoc tests, log transformation, general linear models corrected for age and sex, Pearson/Spearman correlations, ROC/AUC analysis, and Wald’s backward logistic regression for biomarker panels; power was calculated at 88.1%.
Limitations
- Stated by the authors: small sample size in each clinical group, heterogeneity within the FTD group, and lack of FTD stratification by genetic diversity or disease severity; loss of MMSE associations after stratification may reflect low sample size and overlapping pathologies.
- Evident from the text: this is a pilot/exploratory, cross-sectional cohort without an independent validation cohort, and the SCD group was younger and had higher MMSE scores than the disease groups.
- Evident from the text: FTD diagnoses were all probable behavioral variant, and diagnoses were clinical rather than neuropathologically confirmed, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
6 Valid · 2 Not valid · 15 Not checked · 69 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Of particular note is the evidence that no synaptic proteins were not associated with CSF NfL in any clinical group, concurrent with data from other recent cohorts [1, 9, 29].”
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Discussion
What the sources say
- Disputedcites [1] Sogorb-Esteve A, Nilsson J, Swift IJ, Heller C, Bocchetta M, Russell LL, et al. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia. Alzheimers Res Ther. 2022;14(1):118-. sourceExperimental — accuracy not yet measured
The Results section (‘Correlations of synaptic markers with other biomarkers’; page unavailable) reports a significant correlation between CSF NPTX1 and NfL in presymptomatic MAPT carriers. Table 3 also reports significant NPTXR–NfL correlations in symptomatic C9orf72 and MAPT carriers. Moreover, the Methods specify that the NfL measured was in plasma, not CSF. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [9] Kivisäkk P, Carlyle BC, Sweeney T, Quinn JP, Ramirez CE, Trombetta BA, et al. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):58-. sourceExperimental — accuracy not yet measured
The Results section, “CSF levels of PSD-95, SNAP-25, and Ng correlated…” (page unavailable), reports no correlations between the three synaptic markers and NfL within the AD group; Table 2 also lists all three NfL correlations as nonsignificant. These passages do not establish the absence of associations in every clinical group or the claimed agreement with other recent cohorts. (LLM, conf=0.85)
- Could not verifycites [29] Cervantes González A, Irwin DJ, Alcolea D, McMillan CT, Chen-Plotkin A, Wolk D, et al. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Mol Neurodegener. 2022;17(1):29. sourceExperimental — accuracy not yet measured
The section ‘Correlation between antemortem CSF levels of the synaptic proteins’ reports correlations among synaptic proteins across neuropathological groups, but not associations with CSF NfL. Searches for ‘NfL’ and ‘neurofilament light chain’ found no passage in our copy addressing the claimed absence of such associations; the claim’s comparison with other cohorts is likewise not established here. Page numbers were unavailable in the indexed passages. (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to the above concern, even though classical biomarkers such as Aβ42, Tau, and PTau are accepted clinical diagnostic hallmarks of AD, they are not predictive of cognitive decline [9].”
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Background
What the sources say
- Partly supportedcites [9] Kivisäkk P, Carlyle BC, Sweeney T, Quinn JP, Ramirez CE, Trombetta BA, et al. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):58-. sourceExperimental — accuracy not yet measured
The Background (p. null) of our copy states that 'established cerebrospinal fluid (CSF) AD biomarkers such as amyloid-ß42 (Aß42) and phospho-tau (pTau181) have proven to be of diagnostic value in AD, they are less predictive of cognitive decline', and the Abstract frames this as 'a lack of reliable and easily accessible biomarkers predicting cognitive decline in AD'. That supports the diagnostic-hallmark plus poor-prediction thrust of the citing sentence, but two parts attributed here are not in the source: total tau (tTau) is never named among the classical biomarkers said to be poorly predictive (tTau appears only as a correlate of the synaptic markers in Results/Table 2), and the source hedges comparatively ('less predictive', 'it is unclear how well their levels reflect clinically relevant changes during disease progression or treatment trials') rather than asserting flatly that they are 'not predictive'. Note also that this is Kivisäkk et al.'s framing of the field, not an original longitudinal prediction analysis by the paper itself. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recent proteomic analysis of CSF revealed a panel of synaptic biomarkers that were expressed differentially through the progression of AD disease stages.”
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Background
What the sources say
- Supportedcites [5] Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid*. Mol Cell Proteomics. 2019;18(3):546–60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the synaptic proteins correlated to neurofilament light (NfL) in any clinical group.”
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, FTD patients had significantly lower NPTX2 levels than the SCD group (Fig. 2D).”
- Also stated in: § Discussion · plain
“In this cohort, the NPTX2 levels were significantly lower in FTD patients compared to SCD.”
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Results > Levels of synaptic proteins SNAP25, VAMP2, and Ng are elevated in CSF of patients with AD and FTD
plainn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
33 more claims
Create a free account to see all 92 claims and to verify the 21 references still open.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Synaptic protein Ng was measured using a commercial ELISA from EuroImmun, while the other synaptic proteins SNAP25, NPTX2, and GluR4 were measured using novel immunoassays developed and validated as per standardized protocols at ADx NeuroSciences, described in detail elsewhere [15,36,37].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Discussion
“the association of GluR4 with all CSF biomarkers (except NfL) in the SCD group”
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Results > Synaptic biomarkers revealed a differential association with classical fluid biomarkers
“although no significant correlations were found between GluR4 and Ng or NPTX2.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Results > Diagnostic potential of the synaptic biomarkers and selection of panels for differential diagnosis
“Tau | 0.98 (0.99, 1.00)”
§ Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia > Results > Diagnostic potential of the synaptic biomarkers and selection of panels for differential diagnosis
“Note: The data is represented as AUC (95% confidence interval).”
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000410 · Cited by 5,939
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., et al. (2020) · Experimental Physiology · doi:10.1113/ep088870 · Cited by 3,497
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 1×
“The pathological signature of AD is amyloid beta (Aβ) plaque accumulation in the neocortex of the brain, while in FTD, there is degeneration of the frontal and temporal lobes, including in para-limbic areas [4, 5].”
BackgroundThe prevalence of frontotemporal dementia
Ratnavalli, E., Brayne, C., Dawson, K., & Hodges, J. R. (2002) · Neurology · doi:10.1212/wnl.58.11.1615 · Cited by 1,157
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000 · cited 1×
“The current advancements in cerebrospinal fluid (CSF) biomarkers for neurodegenerative dementias have revolutionized the clinical approach towards these disorders, not only for their diagnostic value but also for disease prognosis and critical therapeutic interventions [12, 13].”
BackgroundA practical guide to immunoassay method validation
Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00179 · Cited by 546
Self-citationCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · cited 1×
“The current advancements in cerebrospinal fluid (CSF) biomarkers for neurodegenerative dementias have revolutionized the clinical approach towards these disorders, not only for their diagnostic value but also for disease prognosis and critical therapeutic interventions [12, 13].”
BackgroundAmsterdam Dementia Cohort: Performing Research to Optimize Care
van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170850 · Cited by 390
Ducharme, S., Dols, A., Laforce, R., Devenney, E., Kumfor, F., van den Stock, J., Dallaire-Théroux, C., Seelaar, H., Gossink, F., Vijverberg, E., et al. (2020) · Brain · doi:10.1093/brain/awaa018 · Cited by 320
Self-citation
Research works printed but not linked: 1
- Jacobs D, Delacourt J, Vanbrabant J, Dewit N, Galasko D, Vanmechelen E. A monoconal antibody based immunoassay for Neuronal Pentraxin2 in CSF. AnnuRevImmunol. 2017;6(2):337–66.
Cited by
Nilsson, J., Binette, A. P., Palmqvist, S., Brum, W. S., Janelidze, S., Ashton, N. J., Spotorno, N., Stomrud, E., Gobom, J., Zetterberg, H., et al. (2024) · Brain · doi:10.1093/brain/awae032 · Cited by 92
“11,38,39 40-43 Lastly, β -synuclein belongs to the same pre-synaptic family as alpha-synuclein, a protein prominently known as a major component of Lewy bodies and A β plaques.”
BackgroundThe Role and Pathogenesis of Tau Protein in Alzheimer’s Disease
Hong, X., Huang, L., Lei, F., Tian, L., Luo, Y., Zeng, M., & Wang, Z. (2025) · Biomolecules · doi:10.3390/biom15060824 · Cited by 74
“Furthermore, the study revealed that in the tau proteinopathy model, key proteins on the synaptic vesicle membrane, including syntaxin and synaptobrevin [109,110], exhibited altered binding affinities for tau proteins.”
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
Synapse vulnerability and resilience underlying Alzheimer’s disease
Taddei, R. N., & Duff, K. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105557 · Cited by 51
“101 Synapse proteins measured in CSF and plasma show stage-speci fi c changes in AD that are closely associated with cognitive dysfunction and progression 89 (Fig.”
Wang, J., Huang, Q., Chen, X., You, Z., He, K., Guo, Q., Huang, Y. H., Yang, Y., Lin, Z., Guo, T., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02501-z · Cited by 49
“However, further therapeutic approaches targeting tau and synapses need to consider the in fl uence of both factors.”
Metadata
- Authors
- Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E.
- Affiliations
- Amsterdam Neuroscience (NL)
- ADx NeuroSciences (BE)
- Corresponding author
- Vanmechelen, Eugeen
- ORCID
- Venue
- Alzheimer's Research & Therapy
- Published
- 2023-03-24
- Volume
- 15
- Issue
- 1
- Pages
- 62-62
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC10037899
- OpenAlex
- W4360863494
- Cited by
- 50
- References
- 34
- Citations by year
- 2026: 3 · 2025: 19 · 2024: 26 · 2023: 2
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- H2020 European Institute of Innovation and Technology (860197, 18HLT09)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- synaptic biomarkers, cerebrospinal fluid, Alzheimer's disease, frontotemporal dementia, subjective cognitive decline, SNAP-25, VAMP2, neurogranin, GluR4, tau protein, phosphorylated tau, neurofilament light chain, neurodegeneration, immunoassay development
- MeSH terms
- Alzheimer Disease, Humans, Pilot Projects, Biomarkers, Amyloid beta-Peptides, tau Proteins, Vesicle-Associated Membrane Protein 2, Neurogranin, Frontotemporal Dementia, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia. https://app.cochat.ai/papers/10.1186/s13195-023-01212-x
- The paper
- Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023). Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-023-01212-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.